Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth M Pollack

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 29, 2020
Long-term Outcomes for Extraskeletal Myxoid Chondrosarcoma: A SEER Database AnalysisMichael J Wagner, Bonny Chau, Elizabeth T Loggers, et al.
Cancers|December 11, 2025
The Immune Landscape of Canine Soft Tissue Sarcomas as a Model for Human Soft Tissue SarcomasRegina Hayburn, Dongjun Chung, Arkobato Gupta, et al.
Rare Tumors|January 10, 2025
Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case reportMeghan M Lynch, Pedro Hermida-Viveiros, Sean Stencel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)Lee D Cranmer, Yao Lu, Rachel S Heise, et al.
Cancer Medicine|December 11, 2019
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcomaVictor M Villalobos, Gary Mo, Mark Agulnik, et al.
Plos One|May 6, 2014
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatmentKendall C Shibuya, Vikas K Goel, Wei Xiong, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapyBrett A Schroeder, Ralph Graeme Black, Sydney Spadinger, et al.
Cancers|February 25, 2023
A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with VerteporfinJiyong Liang, Dexing Fang, Joy Gumin, et al.
Clinical Orthopaedics and Related Research|October 14, 2021
Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database AnalysisLee D Cranmer, Bonny Chau, Jose G Mantilla, et al.
Plos One|March 3, 2012
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabineSeth M Pollack, Yonqing Li, Megan J Blaisdell, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 29, 2020
Long-term Outcomes for Extraskeletal Myxoid Chondrosarcoma: A SEER Database AnalysisMichael J Wagner, Bonny Chau, Elizabeth T Loggers, et al.
Cancers|December 11, 2025
The Immune Landscape of Canine Soft Tissue Sarcomas as a Model for Human Soft Tissue SarcomasRegina Hayburn, Dongjun Chung, Arkobato Gupta, et al.
Rare Tumors|January 10, 2025
Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case reportMeghan M Lynch, Pedro Hermida-Viveiros, Sean Stencel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)Lee D Cranmer, Yao Lu, Rachel S Heise, et al.
Cancer Medicine|December 11, 2019
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcomaVictor M Villalobos, Gary Mo, Mark Agulnik, et al.
Plos One|May 6, 2014
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatmentKendall C Shibuya, Vikas K Goel, Wei Xiong, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapyBrett A Schroeder, Ralph Graeme Black, Sydney Spadinger, et al.
Cancers|February 25, 2023
A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with VerteporfinJiyong Liang, Dexing Fang, Joy Gumin, et al.
Clinical Orthopaedics and Related Research|October 14, 2021
Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database AnalysisLee D Cranmer, Bonny Chau, Jose G Mantilla, et al.
Plos One|March 3, 2012
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabineSeth M Pollack, Yonqing Li, Megan J Blaisdell, et al.
Pageof 11